Transgene's Presentation at SITC 2025
Transgene, a pioneering biotech firm in the field of cancer immunotherapy, is set to present groundbreaking data from its Phase I clinical trial of TG4050. This individualized therapeutic cancer vaccine, leveraging innovative virus-based technology, aims to enhance the immune system's response against cancer cells. The presentation will take place at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled for early November 2025.
Highlights of the TG4050 Trial
The Phase I randomized trial has shown promising outcomes in terms of neoantigen-specific T cell responses. Transgene’s poster presentation will detail its findings, showcasing how the individualized treatment has stimulated the immune system in patients undergoing therapy. The emphasis will be on the scientific rigor and the innovative approach that TG4050 embodies in the fight against cancer.
Details About the Presentation
Titled "Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized Phase 1 trial for locally advanced resected HPV negative head and neck squamous cell carcinoma (HNSCC)," the poster will be numbered 502. This significant piece of research will be available for public access following the SITC’s official schedule.
Upcoming Abstract Availability
The abstract for the presentation will be published on the SITC website on November 4, 2025. This will provide an opportunity for the scientific community to engage with the latest findings and understand the implications of TG4050’s effectiveness in cancer immunotherapy.
Innovative Approach with TG4050
Developed utilizing Transgene's proprietary myvac® platform, TG4050 represents a cutting-edge approach to treating solid tumors, particularly HPV-negative forms of head and neck cancers. This individualized immunotherapy not only targets the specific mutations in a patient's cancer but also utilizes advanced artificial intelligence technologies sourced through Transgene’s partnership with NEC. This collaboration aids in optimizing the immunotherapeutic approach tailored to each patient’s unique tumor profile, enhancing treatment efficacy.
Positive Outcomes Reported
Recent updates from Transgene reveal that all patients from the Phase I trial who received TG4050 have remained disease-free after a minimum follow-up period, commendably contrasting with the observational control where three out of 16 patients experienced relapses during the same timeframe.
Future Developments and Trials
Transgene and NEC continue their joint development of TG4050, currently expanding into a Phase II trial that is actively enrolling patients. This ongoing commitment reflects the company’s dedication to developing effective cancer therapies that could significantly improve patient outcomes in the coming years.
About Transgene
Transgene focuses on designing and developing innovative immunotherapies for cancer treatment. Their clinical pipeline includes several viral vector-based immunotherapeutics, with TG4050 being their leading asset, showcasing promising results in targeting cancer effectively. The commitment to personalized medicine is at the core of Transgene's mission, ensuring that each patient receives a tailored treatment plan that aligns with their genetic profile.
Company Contacts
For further inquiries, interested parties can contact:
Media Contact:
Caroline Tosch
Corporate and Scientific Communications Manager
+33 (0)3 68 33 27 38
communication@transgene.fr
Investor Relations:
Lucie Larguier
Chief Financial Officer (CFO)
+33 (0)3 88 27 91 00
investorrelations@transgene.fr
Frequently Asked Questions
What is TG4050?
TG4050 is an individualized therapeutic cancer vaccine developed by Transgene, aimed at enhancing the immune response against solid tumors, particularly head and neck cancers.
When will the findings from the Phase I trial be available?
The findings will be presented at SITC 2025, with the abstract scheduled for release on November 4, 2025.
How does TG4050 work?
TG4050 uses a unique virus-based approach that targets specific mutations within a patient's tumor, customized through advanced AI technology.
What are the expectations for the Phase II trial?
The Phase II trial aims to expand on the promising results seen in Phase I, continuing to evaluate the effectiveness of TG4050 in more patients.
How can I contact Transgene for more information?
Media inquiries can be directed to Caroline Tosch, while investor relations questions can be sent to Lucie Larguier via their respective email addresses.
